Immix Biopharma, Inc.

Immix Biopharma, Inc. (IMMX), a clinical-stage biopharmaceutical company, reported a net loss of $29.4 million for FY 2025, up from $21.7 million in FY 2024, driven by increased operating expenses of $30.0 million versus $22.7 million prior year. Research and development expenses rose to $16.3 million from $11.3 million, reflecting expanded clinical trials for lead candidate NXC-201 in AL Amyloidosis, including NEXICART-2 enrollment. General and administrative expenses increased to $13.7 million from $11.4 million due to higher compensation and professional services. No revenue was generated, as the company remains pre-commercial. Loss per share was -$0.89 (basic and diluted) on 33.0 million weighted shares, compared to -$0.76 in 2024. Balance sheet strengthened with cash and equivalents at $93.9 million and short-term investments $6.5 million, up from prior year end, fueled by $107.4 million in financing proceeds from public offerings and ATM sales. Net cash used in operations was $23.9 million. Total assets reached $104.8 million, equity $93.8 million. Forward-looking, cash supports operations for at least 12 months, with focus on NEXICART-2 readout and BLA submission, amid ongoing CIRM grant funding.

Key Takeaways